| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Clauser E, Curnow KM, Davies E, Conchon S, Teutsch B, Vianello B, Monnot C, Corvol P. Angiotensin II receptors: protein and gene structures, expression and potential pathological involvements. Eur J Endocrinol 1996;134:403–11. ISSN 0804–4643
Two distinct types of cell-surface angiotensin II receptors (AT1 and AT2) have been defined pharmacologically and cDNAs encoding each type have been identified by expression cloning. These pharmacological studies showed the AT1 receptors to mediate all the known functions of angiotensin II in regulating salt and fluid homeostasis. Further complexity in the angiotensin II receptor system was revealed when homology cloning showed the existence of two AT1 subtypes in rodents and in situ hybridization and reverse transcription-polymerase chain reaction analyses showed their level of expression to be regulated differently in different tissues: AT1A is the principal receptor in the vessels, brain, kidney, lung, liver, adrenal gland and fetal pituitary, while AT1B predominates in the adult pituitary and is only expressed in specific regions of the adrenal gland (zona glomerulosa) and kidney (glomeruli). Expression of AT1A appears to be induced by angiotensin II in vascular smooth-muscle cells but is inhibited in the adrenal gland. Preliminary analysis of the AT1 promoters is also suggestive of a high degree of complexity in their regulation. Investigation of a potential role for altered AT1 receptor function has commenced at a genetic level in several diseases of the cardiovascular system. No mutations affecting the coding sequence have been identified in Conn adenoma and no linkage has been demonstrated with human hypertension by sib-pair analysis. None the less, certain polymorphisms that do not alter the protein structure have been found to be associated with hypertension and to occur at an increased frequency in conjunction with specific polymorphisms in the ACE gene in individuals at increased risk for myocardial infarction. Further characterization of the regions of the AT1 gene that regulate its expression are therefore needed. The physiological importance of the AT2 gene product still remains a matter of debate.
E Clauser, INSERM U36, Collège de France, 3 rue d'Ulm, 75005 Paris, France
This article has been cited by other articles:
|
|
 |
|
  H. Lu, C. M. Boustany-Kari, A. Daugherty, and L. A. Cassis Angiotensin II increases adipose angiotensinogen expression Am J Physiol Endocrinol Metab, May 1, 2007; 292(5): E1280 - E1287. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. T. Cowling, X. Zhang, V. C. Reese, M. Iwata, D. Gurantz, W. H. Dillmann, and B. H. Greenberg Effects of cytokine treatment on angiotensin II type 1A receptor transcription and splicing in rat cardiac fibroblasts Am J Physiol Heart Circ Physiol, September 1, 2005; 289(3): H1176 - H1183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Gao, W. Wang, Y.-L. Li, H. D. Schultz, D. Liu, K. G. Cornish, and I. H. Zucker Sympathoexcitation by central ANG II: Roles for AT1 receptor upregulation and NAD(P)H oxidase in RVLM Am J Physiol Heart Circ Physiol, May 1, 2005; 288(5): H2271 - H2279. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Printz The Confluence of Population Genetics with Molecular Pharmacology at the Angiotensin II Receptor: Dawn of a New Era or Just a New Wrinkle? Mol. Pharmacol., March 1, 2004; 65(3): 488 - 491. [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Davisson Physiological genomic analysis of the brain renin-angiotensin system Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2003; 285(3): R498 - R511. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Raiden, K. Nahmod, V. Nahmod, G. Semeniuk, Y. Pereira, C. Alvarez, M. Giordano, and J. R. Geffner Nonpeptide Antagonists of AT1 Receptor for Angiotensin II Delay the Onset of Acute Respiratory Distress Syndrome J. Pharmacol. Exp. Ther., October 1, 2002; 303(1): 45 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Miyajima, T. Kosaka, T. Asano, T. Asano, K. Seta, T. Kawai, and M. Hayakawa Angiotensin II Type I Antagonist Prevents Pulmonary Metastasis of Murine Renal Cancer by Inhibiting Tumor Angiogenesis Cancer Res., August 1, 2002; 62(15): 4176 - 4179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Miserey-Lenkei, Z. Lenkei, C. Parnot, P. Corvol, and E. Clauser A Functional Enhanced Green Fluorescent Protein (EGFP)-Tagged Angiotensin II AT1A Receptor Recruits the Endogenous G{{alpha}}q/11 Protein to the Membrane and Induces Its Specific Internalization Independently of Receptor- G Protein Coupling in HEK-293 Cells Mol. Endocrinol., February 1, 2001; 15(2): 294 - 307. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Raiden, Y. Pereyra, V. Nahmod, C. Alvarez, L. Castello, M. Giordano, and J. Geffner Losartan, a selective inhibitor of subtype AT1 receptors for angiotensin II, inhibits neutrophil recruitment in the lung triggered by fMLP J. Leukoc. Biol., November 1, 2000; 68(5): 700 - 706. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. de Gasparo, K. J. Catt, T. Inagami, J. W. Wright, and Th. Unger International Union of Pharmacology. XXIII. The Angiotensin II Receptors Pharmacol. Rev., September 1, 2000; 52(3): 415 - 472. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Lu, H. Yang, G. Shaw, and M. K. Raizada Angiotensin II-Induced Nuclear Targeting of the Angiotensin Type 1 (AT1) Receptor in Brain Neurons Endocrinology, January 1, 1998; 139(1): 365 - 375. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Conchon, M.-B. Barrault, S. Miserey, P. Corvol, and E. Clauser The C-terminal Third Intracellular Loop of the Rat AT1A Angiotensin Receptor Plays a Key Role in G Protein Coupling Specificity and Transduction of the Mitogenic Signal J. Biol. Chem., October 10, 1997; 272(41): 25566 - 25572. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Gigante, S. Rubattu, R. Russo, A. Porcellini, I. Enea, P. De Paolis, C. Savoia, A. Natale, O. Piras, and M. Volpe Opposite Feedback Control of Renin and Aldosterone Biosynthesis in the Adrenal Cortex by Angiotensin II AT1-Subtype Receptors Hypertension, September 1, 1997; 30(3): 563 - 568. [Abstract] [Full Text]
|
|
|
|
|
|
S. Raiden, M. Giordano, G. Andonegui, A. S. Trevani, D. H. López, V. Nahmod, and J. R. Geffner Losartan, a Selective Inhibitor of Subtype AT1 Receptors for Angiotensin II, Inhibits the Binding of N-Formylmethionyl-leucyl-phenylalanine to Neutrophil Receptors J. Pharmacol. Exp. Ther., May 1, 1997; 281(2): 624 - 628. [Abstract] [Full Text]
|
|
|
|
|
|
L. Ying, B. J. Morris, and C. D. Sigmund Transactivation of the Human Renin Promoter by the Cyclic AMP/Protein Kinase A Pathway Is Mediated by Both cAMP-responsive Element Binding Protein-1 (CREB)-dependent and CREB-independent Mechanisms in Calu-6 Cells J. Biol. Chem., January 24, 1997; 272(4): 2412 - 2420. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
